Skyrizi (Risankizumab) PK Simulator
Indication: Plaque psoriasis
Simulate Skyrizi (risankizumab) pharmacokinetics. This PK simulator models the anti-IL-23 p19 monoclonal antibody used for moderate-to-severe plaque psoriasis.
Drug Overview
Clinical Context
- Molecular Target
- IL-23 p19
- Drug Class
- mAb
- Therapeutic Area
- Immunology
- Indication
- Plaque psoriasis
- Route of Administration
- SC
Model Information
- Model Type
- 2-CMT PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Skyrizi (Risankizumab) allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT PopPK model characterizes the pharmacokinetics of this mab following sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Skyrizi (Risankizumab) PK simulator?
This is a free, interactive pharmacokinetic simulator for Skyrizi (Risankizumab) used in Plaque psoriasis. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Skyrizi (Risankizumab) belong to?
Skyrizi (Risankizumab) is classified as a mAb that targets IL-23 p19. It is used in the Immunology therapeutic area.
What route of administration does this model simulate?
This simulator models SC administration of Skyrizi (Risankizumab). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Xolair (Omalizumab) PK Simulator
Moderate-to-severe allergic asthma
Tremfya (Guselkumab) PK Simulator
Plaque psoriasis
Tecentriq (Atezolizumab) PK Simulator
Non-small cell lung cancer
Stelara (Ustekinumab) PK Simulator
Plaque psoriasis
Rinvoq (Upadacitinib) PK Simulator
Rheumatoid arthritis
Prolia (Denosumab) PK Simulator
Postmenopausal osteoporosis
Ready to Simulate?
Launch the Skyrizi (Risankizumab) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community